Treatment with Upadacitinib in Difficult-to-Treat (D2T) Psoriatic Arthritis (PsA): A National Multicenter Study of the First 134 Patients in Clinical Practice
| Title: | Treatment with Upadacitinib in Difficult-to-Treat (D2T) Psoriatic Arthritis (PsA): A National Multicenter Study of the First 134 Patients in Clinical Practice |
|---|---|
| Authors: | Eva Galíndez-Agirregoikoa; Diana Prieto-Peña; Maria Luz García-Vivar; Joaquin Maria Belzunegui Otano; Beatriz Joven-Ibáñez; Cristina Vergara-Dangond; Marina Pavía-Pascual; Irati Urionaguena-Onaindia; Lucia Vega Alvarez; M. Ángeles Puche Larrubia; Consuelo Ramos Giráldez; Rosario Garcia-Vicuña; Vega Jovani; Angels Martínez-Ferrer; Mireia Moreno Martínez-Losa; Teresa González Hernández; Raquel Almodóvar González; Ana Urruticoechea-Arana; Cristina Macía-Villa; Inigo Gorostiza; Ricardo Blanco Alonso; Upadacitinib PsA Clinical Practice COLLABORATIVE STUDY GROUP Upadacitinib PsA Clinical Practice COLLABORATIVE STUDY GROUP |
| Source: | Sci ; Volume 7 ; Issue 2 ; Pages: 67 |
| Publisher Information: | Multidisciplinary Digital Publishing Institute |
| Publication Year: | 2025 |
| Collection: | MDPI Open Access Publishing |
| Subject Terms: | biologic therapy; clinical practice; psoriatic arthritis; real-world data; upadacitinib; JAK inhibitor; difficult-to-treat PsA |
| Description: | Upadacitinib has demonstrated efficacy in psoriatic arthritis in clinical trials, but its real-world performance in difficult-to-treat PsA remains underexplored. This observational, multicenter, open-label study evaluated the efficacy and safety of upadacitinib in 134 patients with psoriatic arthritis (97 women, mean age 51.8 ± 11.2 years, mean disease duration 9.94 ± 7.72 years) who showed inadequate response to advanced therapies. Most patients (74.6%) had received at least two biological/targeted synthetic disease-modifying antirheumatic drugs with different mechanisms of action. Upadacitinib was initiated at 15 mg daily, and within one month, significant improvements were observed: DAS28-ESR decreased from 4.7 to 3.77 (p < 0.001), DAPSA from 25 to 17 (p < 0.001), and CRP from 2.90 to 1.50 mg/L (p = 0.001). These reductions persisted throughout the study. Prednisone dosage decreased significantly (p = 0.049). Adverse events led to upadacitinib discontinuation in 8.2% of patients, but no serious adverse events were reported. Compared to the SELECT-PsA 2 trial, our cohort had a higher proportion of females and greater prior exposure to biologic agents but showed comparable efficacy and safety outcomes. These findings suggest that upadacitinib is a rapid, effective, and relatively safe therapeutic option for difficult-to-treat psoriatic arthritis under real-world conditions, supporting its use despite differing patient characteristics from clinical trial populations. |
| Document Type: | text |
| File Description: | application/pdf |
| Language: | English |
| Relation: | Biology Research and Life Sciences; https://dx.doi.org/10.3390/sci7020067 |
| DOI: | 10.3390/sci7020067 |
| Availability: | https://doi.org/10.3390/sci7020067 |
| Rights: | https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: | edsbas.E48464B |
| Database: | BASE |